Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery
Cell Stem Cell · 2023-06 · 30 (6) · 766-780.e9
DOI: 10.1016/j.stem.2023.04.017 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cell Stem Cell, 2023-06. Verfasst von Satoru Morimoto und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Neurology, Keio University School of Medicine, Tok…. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Japan, JSPS, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan.
- Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Neurology and Stroke, Saitama Medica…
- Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan.
- Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
- Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan; Keio University Global Research Institute, Tokyo 108-8345, Japan.
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan.
Förderung
- GlaxoSmithKline Japan
- JSPS
- Japan Society for the Promotion of Science
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
- Japan Agency for Medical Research and Development
- National Center of Neurology and Psychiatry
- Uehara Memorial Foundation
Zitieren
APA
Morimoto, S., Takahashi, S., Ito, D., Daté, Y., Okada, K., Kato, C., Nakamura, S., Ozawa, F., Chyi, C. M., Nishiyama, A., Suzuki, N., Fujimori, K., Kondo, T., Takao, M., Hirai, M., Kabe, Y., Suematsu, M., Jinzaki, M., Aoki, M., …, & Okano, H. (2023). Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. Cell Stem Cell, 30(6), 766-780.e9. https://doi.org/10.1016/j.stem.2023.04.017
Vancouver
Morimoto S, Takahashi S, Ito D, Daté Y, Okada K, Kato C, et al. Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. Cell Stem Cell. 2023;30(6):766-780.e9. doi:10.1016/j.stem.2023.04.017
BibTeX
@article{Morimoto2023,
author = {Morimoto, Satoru and Takahashi, Shinichi and Ito, Daisuke and Daté, Yugaku and Okada, Kensuke and Kato, Chris and Nakamura, Shiho and Ozawa, Fumiko and Chyi, Chai Muh and Nishiyama, Ayumi and Suzuki, Naoki and Fujimori, Koki and Kondo, Tosho and Takao, Masaki and Hirai, Miwa and Kabe, Yasuaki and Suematsu, Makoto and Jinzaki, Masahiro and Aoki, Masashi and Fujiki, Yuto and Sato, Yasunori and Suzuki, Norihiro and Nakahara, Jin and Pooled Resource Open-Access ALS Clinical Trials Consortium, Pooled Resource Open-Access ALS Clinical Trials Consortium and Okano, Hideyuki},
title = {Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery},
journal = {Cell Stem Cell},
year = {2023},
volume = {30},
number = {6},
pages = {766--780.e9},
doi = {10.1016/j.stem.2023.04.017}
}
EUVIMED